Skip to main content
← All trials
Moderately to Severely Active Crohns DiseaseDrugPhase 3

What this study is

This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).

What's being tested

  • Afimkibart

    Intervention · DRUG

    Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.

  • Placebo

    Intervention · DRUG

    Placebo matching IV afimkibart.

Study details

Official title
A Phase III, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Patients With Moderately to Severely Active Crohn's Disease
Sponsor
Hoffmann-La Roche
Conditions
Moderately to Severely Active Crohns Disease
Enrolling
425 people
Starts
2025-05-12
Est. completion
2033-04-30
Design
Double-blind, randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗